These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

759 related items for PubMed ID: 19580474

  • 1. Simplified structure of a new model to describe urinary excretion of plutonium after systemic, liver or pulmonary contamination of rats associated with Ca-DTPA treatments.
    Fritsch P, Sérandour AL, Grémy O, Phan G, Tsapis N, Abram MC, Renault D, Fattal E, Benech H, Deverre JR, Poncy JL.
    Radiat Res; 2009 Jun; 171(6):674-86. PubMed ID: 19580474
    [Abstract] [Full Text] [Related]

  • 2. Structure of a single model to describe plutonium and americium decorporation by DTPA treatments.
    Fritsch P, Sérandour AL, Grémy O, Phan G, Tsapis N, Fattal E, Benech H, Deverre JR, Poncy JL.
    Health Phys; 2010 Oct; 99(4):553-9. PubMed ID: 20838098
    [Abstract] [Full Text] [Related]

  • 3. Decorporation of plutonium by pulmonary administration of Ca-DTPA dry powder: a study in rat after lung contamination with different plutonium forms.
    Sérandour AL, Tsapis N, Gervelas C, Grillon G, Fréchou M, Deverre JR, Bénech H, Fattal E, Fritsch P, Poncy JL.
    Radiat Prot Dosimetry; 2007 Oct; 127(1-4):472-6. PubMed ID: 17562654
    [Abstract] [Full Text] [Related]

  • 4. In vitro and in vivo assessment of plutonium speciation and decorporation in blood and target retention tissues after a systemic contamination followed by an early treatment with DTPA.
    Sérandour AL, Grémy O, Fréchou M, Renault D, Poncy JL, Fritsch P.
    Radiat Res; 2008 Aug; 170(2):208-15. PubMed ID: 18666819
    [Abstract] [Full Text] [Related]

  • 5. The CONRAD approach to biokinetic modeling of DTPA decorporation therapy.
    Breustedt B, Blanchardon E, Bérard P, Fritsch P, Giussani A, Lopez MA, Luciani A, Nosske D, Piechowski J, Schimmelpfeng J, Sérandour AL.
    Health Phys; 2010 Oct; 99(4):547-52. PubMed ID: 20838097
    [Abstract] [Full Text] [Related]

  • 6. Biokinetic modelling of DTPA decorporation therapy: the CONRAD approach.
    Breustedt B, Blanchardon E, Berard P, Fritsch P, Giussani A, Lopez MA, Luciani A, Nosske D, Piechowski J, Schimmelpfeng J, Sérandour AL.
    Radiat Prot Dosimetry; 2009 Feb; 134(1):38-48. PubMed ID: 19351653
    [Abstract] [Full Text] [Related]

  • 7. Modelling of bioassay data from a Pu wound treated by repeated DTPA perfusions: biokinetics and dosimetric approaches.
    Fritsch P, Grappin L, Guillermin AM, Fottorino R, Ruffin M, Mièle A.
    Radiat Prot Dosimetry; 2007 Feb; 127(1-4):120-4. PubMed ID: 17562647
    [Abstract] [Full Text] [Related]

  • 8. Enhanced decorporation of plutonium by DTPA encapsulated in small PEG-coated liposomes.
    Phan G, Le Gall B, Grillon G, Rouit E, Fouillit M, Benech H, Fattal E, Deverre JR.
    Biochimie; 2006 Nov; 88(11):1843-9. PubMed ID: 16860919
    [Abstract] [Full Text] [Related]

  • 9. Treatment of human contamination with plutonium and americium: would orally administered Ca- or Zn-DTPA be effective?
    Taylor DM, Hodgson SA, Stradling N.
    Radiat Prot Dosimetry; 2007 Nov; 127(1-4):469-71. PubMed ID: 17556346
    [Abstract] [Full Text] [Related]

  • 10. Plutonium-DTPA Model Application with USTUR Case 0269.
    Konzen K, Brey R, Miller S.
    Health Phys; 2016 Jan; 110(1):59-65. PubMed ID: 26606066
    [Abstract] [Full Text] [Related]

  • 11. Ustur whole body case 0269: demonstrating effectiveness of i.v. CA-DTPA for Pu.
    James AC, Sasser LB, Stuit DB, Glover SE, Carbaugh EH.
    Radiat Prot Dosimetry; 2007 Jan; 127(1-4):449-55. PubMed ID: 18227077
    [Abstract] [Full Text] [Related]

  • 12. Combined drug and surgery treatment of plutonium-contaminated wounds: indications obtained using a rodent model.
    Griffiths NM, Coudert S, Wilk JC, Renault D, Angulo JF, Van der Meeren A.
    Health Phys; 2014 Jun; 106(6):638-44. PubMed ID: 24776894
    [Abstract] [Full Text] [Related]

  • 13. Direct lung delivery of a dry powder formulation of DTPA with improved aerosolization properties: effect on lung and systemic decorporation of plutonium.
    Gervelas C, Serandour AL, Geiger S, Grillon G, Fritsch P, Taulelle C, Le Gall B, Benech H, Deverre JR, Fattal E, Tsapis N.
    J Control Release; 2007 Mar 12; 118(1):78-86. PubMed ID: 17241685
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Developing a physiologically based approach for modeling plutonium decorporation therapy with DTPA.
    Kastl M, Giussani A, Blanchardon E, Breustedt B, Fritsch P, Hoeschen C, Lopez MA.
    Int J Radiat Biol; 2014 Nov 12; 90(11):1062-7. PubMed ID: 24844369
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Decorporation approach following rat lung contamination with a moderately soluble compound of plutonium using local and systemic Ca-DTPA combined chelation.
    Grémy O, Tsapis N, Bruel S, Renault D, Van der Meeren A.
    Radiat Res; 2012 Sep 12; 178(3):217-23. PubMed ID: 22799632
    [Abstract] [Full Text] [Related]

  • 19. Targeting of diethylene triamine pentaacetic acid encapsulated in liposomes to rat liver: an effective strategy to prevent bone deposition and increase urine elimination of plutonium in rats.
    Phan G, Ramounet-Le Gall B, Manceau J, Fanet M, Benech H, Fritsch P, Fattal E, Deverre JR.
    Int J Radiat Biol; 2004 Jun 12; 80(6):413-22. PubMed ID: 15362694
    [Abstract] [Full Text] [Related]

  • 20. Predicting plutonium decorporation efficacy after intravenous administration of DTPA formulations: Study of pharmacokinetic-pharmacodynamic relationships in rats.
    Phan G, Le Gall B, Deverre JR, Fattal E, Bénech H.
    Pharm Res; 2006 Sep 12; 23(9):2030-5. PubMed ID: 16951998
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.